France to Provide Universal Hepatitis C Treatment by Fall 2016

June 10, 2016 After years of limitations, France is now offering immediate hepatitis C virus (HCV) treatment to every HCV-positive person diagnosed with at least stage 2 liver fibrosis in the country. France also plans to provide universal access to the lifesaving cures by September 2016, according to a recent…

Read More

FDA Approves Ocaliva, New Drug for Primary Biliary Cirrhosis (PBC)

June 6, 2016 The U.S. Food and Drug Administration (FDA) has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) to treat primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), Fierce Biotech reports. The drug is approved for use in combination with ursodeoxycholic acid (UDCA) in adults who have responded inadequately…

Read More

CDC Lists 220 Counties at High Risk of HIV and Hepatitis C Outbreaks

June 3, 2016 The Centers for Disease Control and Prevention (CDC) has compiled a list of 220 counties across the nation where injection drug users are especially vulnerable to outbreaks of HIV and hepatitis C, reports The Wall Street Journal. The findings are based on factors such as overdose deaths,…

Read More

AbbVie’s Combo Hepatitis C Treatment Performs Well With All Genotypes

June 1, 2016 AbbVie’s combination treatment of ABT-493 and ABT-530 boasted high cure rates among all genotypes of hepatitis C virus (HCV) in a series of studies, HIVandHepatitis.com reports. Researchers from the Phase IIb SURVEYOR trials conducted various studies among people with genotypes 1 through 6 of hep C who…

Read More